drugset / Trial / NCT06561022
Precision Treatment of HR+ HER2- Advanced Breast Cancer Based on SNF Molecular Subtyping
RandomizedParallel-groupOpen-labelTreatment
Summary
To explore the efficacy and safety of Everolimus (SNF1 subtype) or Fluzoparib (SNF3 subtype) combined with Fulvestrant and Abemaciclib vs. Fulvestrant combined with Abemaciclib in patients with HR+/HER2- breast cancer of SNF1/SNF3 subtype who have progressed after CDK 4/6 inhibitor treatment.
Timeline
- Start
- 2024-08-21
- Primary completion
- 2025-12-31
- Completion
- 2026-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Everolimus | Small molecule | — | — |
| Subject | Fluzoparib | Small molecule | — | — |
| Background | Abemaciclib | Small molecule | — | — |
| Background | Fulvestrant | Small molecule | — | — |